Literature DB >> 24079379

Population susceptibility to North American and Eurasian swine influenza viruses in England, at three time points between 2004 and 2011.

K Hoschler1, C Thompson, I Casas, J Ellis, M Galiano, N Andrews, M Zambon.   

Abstract

Age-stratified sera collected in 2004, 2008 and 2010 in England were evaluated for antibody to swine influenza A(H3N2) and A(H1N1) viruses from the United States or Europe as a measure of population susceptibility to the emergence of novel viruses. Children under 11 years of age had little or no measurable antibody to recent swine H3N2 viruses despite their high levels of antibody to recent H3N2 seasonal human strains. Adolescents and young adults (born 1968–1999) had higher antibody levels to swine H3N2 viruses. Antibody levels to swine H3N2 influenza show little correlation with exposure to recent seasonal H3N2 (A/Perth/16/2009) strains, but with antibody to older H3N2 strains represented by A/Wuhan/359/1995. Children had the highest seropositivity to influenza A(H1N1)pdm09 virus, and young adults had the lowest antibody levels to A/Perth/16/2009. No age group showed substantial antibody levels to A/Aragon/RR3218/2008, a European swine H1N1 virus belonging to the Eurasian lineage. After vaccination with contemporary trivalent vaccine we observed evidence of boosted reactivity to swine H3N2 viruses in children and adults, while only a limited boosting effect on antibody levels to A/Aragon/RR3218/2008 was observed in both groups. Overall, our results suggest that different vaccination strategies may be necessary according to age if swine viruses emerge as a significant pandemic threat.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24079379     DOI: 10.2807/1560-7917.es2013.18.36.20578

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  8 in total

1.  Effect of Priming With Seasonal Influenza A(H3N2) Virus on the Prevalence of Cross-Reactive Hemagglutination-Inhibition Antibodies to Swine-Origin A(H3N2) Variants.

Authors:  Feng Liu; Vic Veguilla; F Liaini Gross; Eric Gillis; Thomas Rowe; Xiyan Xu; Terrence M Tumpey; Jacqueline M Katz; Min Z Levine; Xiuhua Lu
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

2.  Heterologous Antibody Responses Conferred by A(H3N2) Variant and Seasonal Influenza Vaccination Against Newly Emerged 2016-2018 A(H3N2) Variant Viruses in Healthy Persons.

Authors:  Feng Liu; Min Z Levine
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

3.  Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection.

Authors:  Kristien Van Reeth; José Carlos Mancera Gracia; Ivan Trus; Lieve Sys; Gerwin Claes; Han Versnaeyen; Eric Cox; Florian Krammer; Yu Qiu
Journal:  NPJ Vaccines       Date:  2017-04-20       Impact factor: 7.344

Review 4.  Ferret models of viral pathogenesis.

Authors:  T Enkirch; V von Messling
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

5.  Cross-protection against European swine influenza viruses in the context of infection immunity against the 2009 pandemic H1N1 virus: studies in the pig model of influenza.

Authors:  Yu Qiu; Karl De Hert; Kristien Van Reeth
Journal:  Vet Res       Date:  2015-09-24       Impact factor: 3.683

Review 6.  [Middle East respiratory syndrome (MERS): bats or dromedary, which of them is responsible?].

Authors:  C Chastel
Journal:  Bull Soc Pathol Exot       Date:  2014-02-15

7.  Zoonotic infection with swine A/H1avN1 influenza virus in a child, Germany, June 2020.

Authors:  Ralf Dürrwald; Marianne Wedde; Barbara Biere; Djin-Ye Oh; Martina Heßler-Klee; Christian Geidel; Renate Volmer; Anja Maria Hauri; Kai Gerst; Andrea Thürmer; Sandra Appelt; Janine Reiche; Susanne Duwe; Silke Buda; Thorsten Wolff; Walter Haas
Journal:  Euro Surveill       Date:  2020-10

8.  Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group1.

Authors:  Elien Vandoorn; Isabel Leroux-Roels; Geert Leroux-Roels; Anna Parys; Amy Vincent; Kristien Van Reeth
Journal:  Emerg Infect Dis       Date:  2020-09       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.